Bariatric surgery linked to lower risk of psychiatric disorders than GLP-1 drugs
People who have metabolic and bariatric surgery are significantly less likely to develop psychiatric disorders compared to those who take weekly injections of GLP-1 anti-obesity medications, according to a new study presented today at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Scientific Meeting.
ADA (American Diabetes Association) June 20-24 Obesity Medicines – Lilly Posters and Talks
Lilly Orgorglipron Orforglipron is a novel, oral, non-peptide GLP‑1 receptor agonist, and the ACHIEVE‑1 Phase III data demonstrated efficacy and tolerability comparable to existing injectables Oral Presentation – Lilly will feature its oral GLP‑1 candidate, orforglipron, with topline results from its Phase III ACHIEVE‑1 trial showing positive safety, glycemic control, and weight loss (~8 % at 40 weeks). This […]
ADA (American Diabetes Association) June 20-23 Obesity Medicines Novo Nordisk Posters and Talks
Novo CagriSema CagriSema is an investigational medication being developed by Novo Nordisk for the treatment of obesity and type 2 diabetes. It is a fixed-dose combination of two drugs: Cagrilintide: An amylin analog that helps regulate appetite and reduce food intake Semaglutide: A glucagon-like peptide-1 (GLP-1) receptor agonist that improves blood sugar control and promotes weight loss. CagriSema is designed […]
STAT+: Lilly adds highest Zepbound doses to DTC offering
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, let’s get straight to the news today. The need-to-know this morning Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus a CVR potentially worth another $300 million. […]
Ozempic outperforms another diabetes drug for reducing stroke risk
Type 2 diabetes patients taking semaglutide, often sold as Ozempic or Wegovy, have a slightly lower risk of stroke compared to patients taking another diabetes drug—empagliflozin. International researchers studied data from 7,899 patients treated with semaglutide and 7,899 treated with empagliflozin to look for differences in the risk of death, heart attack, stroke, heart failure and an irregular heartbeat.
GLP-1 Drugs Like Ozempic Are Widely Popular. Here Are Side Effects You Should Know About
Glucagon-Like-Peptide-1 Agonists, like Ozempic, have become extremely popular for weight loss. Here are some of the side effects you should know about.
Renewing the Ozempic Patent in Canada Costs Very Little. Surprisingly, Novo Nordisk Has Chosen Not to
Novo Nordisk is the Danish pharmaceutical company that developed semaglutide, the active ingredient in the widely-used Ozempic medication. Notably, the company has failed to pay the maintenance fee for its patent for several years. A million-worth oversight. According to a Science article, Novo Nordisk hasn’t paid the maintenance fee for the semaglutide patent, which currently […]
STAT+: Pharmalittle: We’re reading about a Lilly deal, a gene therapy shock for Duchenne families, and more
Top of the morning to you. Unfortunately, soggy gray skies are enveloping the placid Pharmalot campus, but our spirits remain decidedly sunny, nonetheless. Why? We will trot out a bit of wisdom from the dearly departed Morning Mayor, who taught us that “every new day should be unwrapped like a precious gift.” While you tug […]
Lark Health unveils LarkVantage, an AI-powered tool to manage GLP-1 costs – Fierce Healthcare
Lark Health unveils LarkVantage, an AI-powered tool to manage GLP-1 costs Fierce Healthcare
Oral Semaglutide: Trends Suggest Potential Kidney Benefits
While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn’t match the effects seen with the injectable formulation in the FLOW trial, the observed trends suggest improvements. Medscape Medical News